Treatment of oligometastatic breast cancer: The role of patient selection
Up to 90 % of death from solid tumors are caused by metastases. By 2040, breast cancer (BC) is predicted to increase to over 3 million new cases. Additionally, with the personalization and intensification of BC follow-up, many patients will relapse with oligometastatic disease (OMD). Over the past d...
Saved in:
Main Authors: | Riccardo Ray Colciago, Maria Carmen De Santis, Carlotta Giandini, Maria Grazia Carnevale, Serena Di Cosimo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Breast |
Online Access: | http://www.sciencedirect.com/science/article/pii/S096097762400170X |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial
by: Michael Ghadimi, et al.
Published: (2025-02-01) -
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01) -
The Multifaceted Roles of Myrrha in the Treatment of Breast Cancer: Potential Therapeutic Targets and Promises
by: Anwar Shams MD, MSc, PhD, et al.
Published: (2024-12-01) -
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer
by: Brenno Pastò, et al.
Published: (2025-02-01) -
Genetic advancements in breast cancer treatment: a review
by: Marzieh Shokoohi, et al.
Published: (2025-02-01)